268 related articles for article (PubMed ID: 31655611)
61. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
Halefoglu AM; Ozagari AA
Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
[TBL] [Abstract][Full Text] [Related]
62. Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.
Zieren RC; Dong L; Clark DJ; Kuczler MD; Horie K; Moreno LF; Lih TM; Schnaubelt M; Vermeulen L; Zhang H; de Reijke TM; Pienta KJ; Amend SR
Med Oncol; 2021 Jul; 38(9):105. PubMed ID: 34331598
[TBL] [Abstract][Full Text] [Related]
63. HNF-1β as an immunohistochemical marker for distinguishing chromophobe renal cell carcinoma and hybrid oncocytic tumors from renal oncocytoma.
An J; Park CK; Kim M; Joo JW; Cho NH
Virchows Arch; 2021 Mar; 478(3):459-470. PubMed ID: 32816058
[TBL] [Abstract][Full Text] [Related]
64. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma.
Ni D; Ma X; Li HZ; Gao Y; Li XT; Zhang Y; Ai Q; Zhang P; Song EL; Huang QB; Fan Y; Zhang X
Clin Cancer Res; 2014 Apr; 20(7):1779-90. PubMed ID: 24486593
[TBL] [Abstract][Full Text] [Related]
65. SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization.
Ferreira MJ; Pires-Luís AS; Vieira-Coimbra M; Costa-Pinheiro P; Antunes L; Dias PC; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2017; 12(12):1057-1064. PubMed ID: 29099276
[TBL] [Abstract][Full Text] [Related]
66. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.
Kruck S; Hennenlotter J; Vogel U; Schilling D; Gakis G; Hevler J; Kuehs U; Stenzl A; Schwentner C
BJU Int; 2012 Feb; 109(4):634-8. PubMed ID: 21711439
[TBL] [Abstract][Full Text] [Related]
67. HNF1β and S100A1 are useful biomarkers for distinguishing renal oncocytoma and chromophobe renal cell carcinoma in FNA and core needle biopsies.
Conner JR; Hirsch MS; Jo VY
Cancer Cytopathol; 2015 May; 123(5):298-305. PubMed ID: 25739652
[TBL] [Abstract][Full Text] [Related]
68. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract][Full Text] [Related]
69. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
[TBL] [Abstract][Full Text] [Related]
70. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
71. Differentiation of subtypes of renal cell carcinoma with contrast-enhanced ultrasonography.
Xue LY; Lu Q; Huang BJ; Li CX; Yan LX; Wang WP
Clin Hemorheol Microcirc; 2016 Oct; 63(4):361-371. PubMed ID: 26598999
[TBL] [Abstract][Full Text] [Related]
72. Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma.
Zhao Z; Lu J; Qu H; Wang Z; Liu Q; Yang X; Liu S; Ge J; Xu Y; Li N; Yuan Y
Hum Pathol; 2018 Oct; 80():87-93. PubMed ID: 29935195
[TBL] [Abstract][Full Text] [Related]
73. Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.
Zhou L; Liu S; Li X; Yin M; Li S; Long H
Mol Med Rep; 2019 May; 19(5):3485-3496. PubMed ID: 30896867
[TBL] [Abstract][Full Text] [Related]
74. Epithelial to Mesenchymal Transition in Clear Cell Renal Cell Carcinoma with Rhabdoid Features.
Sugimoto M; Kohashi K; Itsumi M; Shiota M; Abe T; Yamada Y; Kuroiwa K; Naito S; Oda Y
Pathobiology; 2016; 83(6):277-86. PubMed ID: 27225469
[TBL] [Abstract][Full Text] [Related]
75. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
Gowrishankar B; Ibragimova I; Zhou Y; Slifker MJ; Devarajan K; Al-Saleem T; Uzzo RG; Cairns P
Cancer Biol Ther; 2014 Mar; 15(3):329-41. PubMed ID: 24351440
[TBL] [Abstract][Full Text] [Related]
76. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma.
Campagna R; Cecati M; Pozzi V; Fumarola S; Pompei V; Milanese G; Galosi AB; Sartini D; Emanuelli M
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):51-55. PubMed ID: 29974846
[TBL] [Abstract][Full Text] [Related]
77. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
78. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
79. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
Tan MH; Wong CF; Tan HL; Yang XJ; Ditlev J; Matsuda D; Khoo SK; Sugimura J; Fujioka T; Furge KA; Kort E; Giraud S; Ferlicot S; Vielh P; Amsellem-Ouazana D; Debré B; Flam T; Thiounn N; Zerbib M; Benoît G; Droupy S; Molinié V; Vieillefond A; Tan PH; Richard S; Teh BT
BMC Cancer; 2010 May; 10():196. PubMed ID: 20462447
[TBL] [Abstract][Full Text] [Related]
80. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases.
Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
Mod Pathol; 2004 Feb; 17(2):180-8. PubMed ID: 14657952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
